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DEAR EDITOR, Hidradenitis suppurativa (HS) is a chronic inflam-
matory skin disease with multiple inflammatory skin lesions
(‘boils’) in flexural locations.1 Prevalence of HS remains con-
troversial2,3 and the study aim was to search the Secure Anon-
ymised Information Linkage (SAIL) Databank to identify
diagnosed and undiagnosed HS cases in Wales, UK.
The SAIL Databank provides access to routinely collected
primary care data, linked to Patient Episode Database for
Wales (PEDW) data, covering 25 million individuals within
the Welsh population of just over 3 million people.4 The
prevalence of diagnosed cases of HS was determined using
Read Codes M25y1 and M25y111. Undiagnosed ‘proxy’ cases
were identified using the skin boil algorithms developed and
validated for the UK Clinical Practice Research Datalink
(CPRD).3 The algorithms require a record of at least five skin
boils, on separate occasions within the primary care databank.
Validation in CPRD makes use of General Practitioner (GP)
questionnaires, which are limited by GPs having several thou-
sand patients under their care, and so GPs themselves are often
reliant on the electronic record. While SAIL does not have
access to GP validation, it is linked to HealthWise Wales
(HWW), a register of people willing to take part in research
and return health questionnaires.5
An online questionnaire was sent to HWW participants to
identify outbreaks of skin ‘boils’ during the previous 6 months
in flexural locations and a minimum of two boils. The question-
naire has a published specificity of 97% and a sensitivity of 90%
in identifying people with HS.6 Of the 1481 SAIL participants
who answered the questionnaire, 86 (58%) gave responses
consistent with HS. Five of these individuals had a HS Read Code
in SAIL and 14 were identified by the CPRD algorithms. Manu-
ally checking a representative sample of the other 67 positive
respondents, there were no relevant consultations, such as for
skin boils or pilonidal sinus, recorded in SAIL. Due to a lack of
data, validation of CPRD algorithms was possible for subalgo-
rithm 2(b) only, for which eight HWW respondents gave posi-
tive responses and 31 were negative for HS (21% positive rate).
As a consequence, validation data were taken from the CPRD
study for the other subalgorithms.3
From the SAIL population of 2 531 943 individuals,
11 397 had an HS diagnosis in SAIL up to 30 June 2017.
A further 1585 SAIL patients were treated for HS in sec-
ondary care as identified by PEDW data. Hence, the point
prevalence of diagnosed HS in the Welsh population was
51 per 1000, or 051%. Application of the CPRD hierarchi-
cal subalgorithms identified 74 594 additional proxy cases,
reduced to 14 435 criteria-diagnosed cases after validation,
using the conversion factors developed in the CPRD study3
and the HWW-validated conversion factor for subalgorithm
2(b). Overall HS prevalence is therefore 108 per 1000, or
108% (Figure 1).
Of the 100 HS patients attending a specialist secondary care
HS clinic in Wales, 85 of the cohort were present in SAIL, 72
as diagnosed cases and a further nine within the subalgo-
rithms, with four cases not captured. This confirms relatively
high capture of secondary care HS cases by SAIL, with 85%
correctly transcribed into the primary care record and only 5%
missed by either the diagnostic code or a subalgorithm.
During the period from 2000 to 2016, the number of
newly diagnosed HS cases per year increased nearly fourfold,
from 200 to 765, likely owing to increasing recognition of
HS. The female-to-male ratio of newly diagnosed cases was
3 : 1 and peak age of diagnosis was in the third decade of
life.
Limitations of the study include a relatively short time
frame for HWW data collection, which was only able to vali-
date subalgorithm 2(b) in this cohort. However, CPRD covers
Wales, as well as the English population, and so validation
data for CPRD will also be valid for the Welsh population.
The 58% rate of positive returns from the HWW question-
naire is high and indicates a degree of case ascertainment bias.
Lack of relevant SAIL consultations in most of this group sug-
gests that either the individuals had mild disease or they chose
not to see their GP, or both. Our prevalence figure may be an
underestimate because HWW data were used only as a valida-
tion tool for SAIL data.
Comparing the SAIL results with prevalence figures from
CPRD, there is quite close agreement. Prevalence of diag-
nosed cases in CPRD was 54 per 1000 (054%).3 Prevalence
of HS in CPRD rose to 077% when validated proxy cases
were included, and 119% when probable cases with a his-
tory of 1–4 flexural skin boils on separate occasions were
included.3 The SAIL prevalence of 108% adds further weight
to the evidence that HS is a relatively common condition in
the UK.
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SAIL populaon = 2 531 943
HS diagnosc Read Codes = 11 397 
individuals
Proxy cases from applicaon of 
CPRD subalgorithms = 74 594
Addional individuals receiving HS 
treatment in hospital = 1585
Conversion factors applied from 
CPRD study and HWW responses  
= 14 435 validated cases
Total cases = 27 417
Prevalence = 27 417/ 2 531 943
= 1.08%
Figure 1 Data sources and their contributions to the overall hidradenitis suppurativa (HS) prevalence figure and validation process. SAIL, Secure
Anonymised Information Linkage Databank; CPRD, Clinical Practice Research Datalink; HWW, HealthWise Wales.
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